UY31469A1 - Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos - Google Patents

Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos

Info

Publication number
UY31469A1
UY31469A1 UY31469A UY31469A UY31469A1 UY 31469 A1 UY31469 A1 UY 31469A1 UY 31469 A UY31469 A UY 31469A UY 31469 A UY31469 A UY 31469A UY 31469 A1 UY31469 A1 UY 31469A1
Authority
UY
Uruguay
Prior art keywords
medicines
compounds
new
hydratizes
difenylazetidinone
Prior art date
Application number
UY31469A
Other languages
English (en)
Spanish (es)
Inventor
Dr Wollmann Theodor Andreas
Regina Dr Duffy
Frank Cr Cullmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40386121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31469A1 publication Critical patent/UY31469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY31469A 2007-11-13 2008-11-13 Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos UY31469A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007063671A DE102007063671A1 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102007054497A DE102007054497B3 (de) 2007-11-13 2007-11-13 Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
UY31469A1 true UY31469A1 (es) 2009-07-17

Family

ID=40386121

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31469A UY31469A1 (es) 2007-11-13 2008-11-13 Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos

Country Status (11)

Country Link
US (1) US8003636B2 (enExample)
EP (1) EP2220040B1 (enExample)
JP (1) JP5401463B2 (enExample)
AR (1) AR069305A1 (enExample)
CL (1) CL2008003358A1 (enExample)
DE (2) DE102007054497B3 (enExample)
PA (1) PA8803701A1 (enExample)
PE (1) PE20091165A1 (enExample)
TW (1) TW200936566A (enExample)
UY (1) UY31469A1 (enExample)
WO (1) WO2009062619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
CN101939009B (zh) * 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
DK2273994T3 (en) 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE
AU2013362400B2 (en) * 2012-12-22 2016-07-28 Novo Nordisk A/S Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
WO2015112588A1 (en) 2014-01-22 2015-07-30 Biomimetix Jv, Llc Methods of treating skin disorders

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CZ293957B6 (cs) 1995-10-31 2004-08-18 Scheringácorporation @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
IL125071A0 (en) * 1996-01-17 1999-01-26 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
JP4339402B2 (ja) 1996-12-31 2009-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物、並びに糖尿病及び関連疾患の治療におけるこれらの使用
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69917237T2 (de) * 1998-03-12 2005-05-04 Teijin Ltd. Benzofurylpyron-derivate
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
SG125915A1 (en) 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
JP2003502369A (ja) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
PT1204654E (pt) 1999-07-29 2003-11-28 Lilly Co Eli Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
WO2001016094A1 (de) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
AU2001233622A1 (en) 2000-02-25 2001-09-03 Novo-Nordisk A/S Inhibition of beta cell degeneration
WO2001083451A1 (en) * 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002008188A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
HUP0004741A2 (hu) 2000-11-28 2002-12-28 Sanofi-Synthelabo Kémiai eljárás tiazolszármazékok előállítására és új intermedier
ES2277890T3 (es) * 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
HUP0401073A2 (hu) 2000-12-21 2004-09-28 Aventis Pharma Deutschland Gmbh. Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
GB0113233D0 (en) 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL160556A0 (en) * 2001-08-31 2004-07-25 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
US6884812B2 (en) * 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2003097064A1 (en) 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2003249937A1 (en) 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
WO2004097655A1 (ja) 2003-04-25 2004-11-11 Matsushita Electric Industrial Co. Ltd. マルチメディア情報共有システム
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
AU2004255285A1 (en) 2003-07-09 2005-01-20 Forbes Medi-Tech Inc Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
US20070072812A1 (en) 2003-08-25 2007-03-29 Microbia, Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US20070161577A1 (en) 2003-08-28 2007-07-12 Martinez Eduardo J Tethered dimers and trimers of 1,4-diphenylazetidin-2-ones
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
JP2007509963A (ja) 2003-10-30 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血漿薬としての２−アゼチジノン
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
PL380414A1 (pl) 2003-11-10 2007-01-22 Microbia, Inc. 4-Diarylo-1- fenyloazetydyn-2-ony
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ES2290782T3 (es) 2004-01-06 2008-02-16 Janssen Pharmaceutica N.V. Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuestos aferentes como inhibidores de la glucogeno fosforilasa en el tratamiento de la diabetes y de la obesidad.
DE102004006325A1 (de) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
DK1751131T3 (da) 2004-03-10 2009-03-16 Janssen Pharmaceutica Nv MTP-inhiberende arylpiperidiner eller -piperaziner, der er substitueret med 5-leddede heterocykler
US20080096922A1 (en) 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
EP1734930A2 (en) 2004-04-09 2006-12-27 Smithkline Beecham Corporation Low dose pharmaceutical products
DE102004025072A1 (de) * 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
FR2871463B1 (fr) 2004-06-11 2006-09-22 Merck Sante Soc Par Actions Si Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
FR2873368B1 (fr) 2004-07-26 2008-01-04 Merck Sante Soc Par Actions Si Derives de guanidine et leurs utilisations en therapeutique
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
AU2005284485A1 (en) 2004-09-11 2006-03-23 Sanofi-Aventis Deutschland Gmbh 7-azaindoles and their use as PPAR agonists
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
BRPI0517458A (pt) 2004-10-22 2008-10-07 Smithkline Beecham Corp derivados da xantina com atividade para o receptor hm74a
WO2006059744A1 (ja) 2004-11-30 2006-06-08 Nippon Chemiphar Co., Ltd. ペルオキシソーム増殖剤活性化受容体δの活性化剤
AU2005324127A1 (en) 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
MX2007007553A (es) 2004-12-24 2007-08-15 Prosidion Ltd Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1843763A2 (en) 2005-02-03 2007-10-17 Irm, Llc Compounds and compositions as ppar modulators
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
FR2883000B1 (fr) 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JP2008536846A (ja) 2005-04-13 2008-09-11 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、かかる化合物を含有する組成物及び治療方法
JP2008539255A (ja) 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
JP2008539735A (ja) 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
MX2007014172A (es) 2005-05-11 2008-04-02 Microbia Inc Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
EA012442B1 (ru) 2005-05-13 2009-10-30 Эли Лилли Энд Компани Пегилированные соединения glp-1
EP1885726B1 (en) 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2006127893A2 (en) 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
EP1893222A4 (en) 2005-06-15 2010-07-07 Merck Sharp & Dohme ANTI-HYPERCHOLESTERINAMIC COMPOUNDS
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR056866A1 (es) 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US7067689B1 (en) * 2005-07-08 2006-06-27 Microbia, Inc. Process for production of pentahydroxyhexylcarbamoyl alkanoic acids
JP2007022943A (ja) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd スクアレン合成酵素阻害薬
DE102005033100B3 (de) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
JP2009504592A (ja) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
WO2007027532A2 (en) 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
NZ566878A (en) 2005-09-29 2010-07-30 Sanofi Aventis Phenyl-and pyridinyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007041494A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
WO2009112203A1 (de) * 2008-03-14 2009-09-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur herstellung eines diphenylazetidinons

Also Published As

Publication number Publication date
DE102007054497B3 (de) 2009-07-23
JP5401463B2 (ja) 2014-01-29
US8003636B2 (en) 2011-08-23
JP2011503127A (ja) 2011-01-27
PE20091165A1 (es) 2009-08-31
AR069305A1 (es) 2010-01-13
DE102007063671A1 (de) 2009-06-25
EP2220040A1 (de) 2010-08-25
TW200936566A (en) 2009-09-01
WO2009062619A1 (de) 2009-05-22
PA8803701A1 (es) 2009-06-23
CL2008003358A1 (es) 2009-06-26
EP2220040B1 (de) 2013-01-16
US20090203578A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
UY29675A1 (es) Nuevos derivados de 1,1-dióxido de 1,4-benzotiazepina con mejores propiedades, procedimiento para su preparacion, medicamentoss que comprenden este compuestoy su uso.
UY31469A1 (es) Nuevos hidratos de difenilazetidinona cristalinos, medicamentos que comprenden a estos compuestos y uso de los mismos
ECSP13012519A (es) Compuestos sustituidos de benzamida
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CR20110059A (es) Compuestos organicos
EA201100037A1 (ru) Органические соединения
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY30682A1 (es) Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico con propiedades farmacologicas mejoradas
CL2007002519A1 (es) Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina
UA110802C2 (uk) Моногідрат похідного азаадамантану
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
GT200500311A (es) Compuestos organicos
ES2647545T3 (es) Composición aromatizante
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121119